Loading clinical trials...
Loading clinical trials...
A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors
Conditions
Interventions
BMS-986178
Nivolumab
+4 more
Locations
22
United States
University Of Colorado
Aurora, Colorado, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Columbia University Medical Center (Cumc)
New York, New York, United States
Providence Portland Medical Center
Portland, Oregon, United States
Start Date
June 17, 2016
Primary Completion Date
November 2, 2020
Completion Date
November 2, 2020
Last Updated
January 25, 2022
NCT05735080
NCT04657068
NCT04900818
NCT05004116
NCT07009886
NCT06440005
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions